pluristem therapeutics inc
(PSTI:Consolidated Issue listed on NASDAQ Capital Market)
Frank C. Carlucci
Head of Strategic Business Advisory Board, Pluristem Therapeutics, Inc.
|Age||Total Calculated Compensation||This person is connected to 87 board members in 12 different organizations across 20 different industries.|
See Board Relationships
Mr. Frank C. Carlucci is a Senior Advisor and Member of Advisory Board of Monument Capital Group Holdings LLC. He is a Co-Founder of Frontier Group. Mr. Carlucci serves as Counselor of Center for Strategic and International Studies, Inc. He served as a Managing Director of The Carlyle Group since 1989. Since 1993, Mr. Carlucci served as the Partner of The Carlyle Group and also served as its Vice Chairman from 1989 to 1993. He served as the Chief Executive Officer and ...
MATAM Advanced Technology ParkPhone: 972 7 4710 8759
Haifa, -- 31905
Fax: 972 7 4710 8765
Board Members Memberships*
Former Chairman of the Board
Former Director and Member of Compensation & Corporate Governance Committee
Director and Member of Nominating and Corporate Governance Committee
Vice Chairman, Member of Compensation Committee, Member of Audit Committee and Member of Executive Committee
Vice Chairman, Member of Nomination & Corporate Governance Committee and Member of Compensation Committee
Harvard Business School
Honorary Doctorate 1989
University of Scranton
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Gil Van Bokkelen Ph.D.||Co-Founder, Chairman and Chief Executive Officer|
|Robin C. Stracey||Chief Executive Officer and Director|
Cesca Therapeutics Inc.
|Martin M. McGlynn||Chief Executive Officer, Director, Member of Strategic Transactions Committee, Chief Executive Officer of Stemcells California Inc and President of Stemcells California Inc|
|David J. Mazzo B.A (Hons), B.Sc. (Hons.), M.Sc., Ph.D.||Chief Executive Officer and Director|
Caladrius Biosciences, Inc.
|Martin P. Rosendale||Chief Executive Officer and Director|
Nuo Therapeutics, Inc.
|$385.0K||Compensation as of Fiscal Year 2014.|